



## Now Indicated for Dissection of the Descending Thoracic Aorta

### Low Profile Without Compromise

- ▶ Wide range of tapers to better fit patients' anatomy
- ▶ Dual sheath designed for atraumatic device delivery
- ▶ Low profile system with both bare stent and non-bare stent configurations provides broad treatment options

# RelayPro demonstrates excellent performance and early survival benefit in acute, complicated TBAD

RelayPro was studied in a prospective IDE clinical study with 22 centers in the United States that included 56 subjects with acute, complicated Type B dissection

## Primary endpoint:

30 day all-cause mortality

## Secondary endpoints:

technical success, major adverse events (disabling stroke, renal failure, paraplegia, paraparesis), endoleaks, patency, rupture, device integrity, kinking/twisting, false lumen perfusion, reinterventions, aortic expansion, and migration through 5 years.

## Highly Complex Patient Population:

**52%**

renal malperfusion

**36%**

lower extremity malperfusion

**34%**

visceral malperfusion

**11%**


rupture

- ▶ Proximal extent of dissection zones 1/2: **14%**
- ▶ LSA coverage: **60%**
- ▶ Distal extent of dissection in the iliacs: **63%**

- ▶ Most procedures were percutaneous: **85.5%**
- ▶ Low **1.8%** 30-Day all-cause mortality shows an early survival benefit
- ▶ RelayPro NBS: **65.3%** of devices implanted in study



RelayPro NBS is a valuable addition to dissection treatment options



Images courtesy of Dr. Wilson Szeto, UPenn

## Key outcomes

**1.8%**

All-Cause Mortality at 30 days

**85%**

Freedom from All-Cause Mortality through 12 months

**89%**

Freedom from MAEs (disabling stroke, renal failure, paraplegia, paraparesis) through 12 months

**100%**

Technical Success\*

**94%**

Dissection Treatment Success at 12 months

**1.8%**

Type Ia Endoleaks through 12 months

**0%**

Type Ib Endoleaks through 12 months

**1.8%**

Migration through 12 months

**100%**

Patency through 12 months

**0%**

No Fractures through 12 months

**0%**


No Type II and Type III Endoleaks

\*Technical Success at the time of the index procedure, defined as successful delivery and deployment of the device, including withdrawal of the delivery system.

All patients should be advised that endovascular treatment requires yearly lifelong imaging and regular follow-up to assess their health and the performance of their endovascular graft.

Bare Stent		
Stent-Graft Diameter	Proximal Length	Distal Length
24 - 28mm	15mm	20mm
30 - 38mm	20mm	20mm
40 - 46mm	25mm	20mm

Non-Bare Stent		
Stent-Graft Diameter	Proximal Length	Distal Length
24 - 38mm	25mm	20mm
40 - 46mm	30mm	20mm



At Terumo Aortic, we are 100% focused on  
addressing every segment of the aorta,  
from the aortic root to the iliacs.

**terumoortic.com**

Discover solutions for every segment of the aorta

Consult Instructions for Use, [eifu.terumoortic.com](http://eifu.terumoortic.com), for more information on use, indications, contraindications and warnings/precautions.

Product availability subject to local regulatory approval.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

 Manufactured by: Bolton Medical Inc, 799 International Parkway, Sunrise, Florida 33325, USA

USA\_0260-A Apr23 • PM-06836

**TERUMO**  
Aortic